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Cardio-metabolic riskDespite the considerable body of evidence pointing to a possible relationship between the state of the adipose
tissue depots and regulation of the somatotropic axis, to date the relationship between obesity and low growth
hormone (GH) status remains incompletely understood. The low GH status in obesity is mainly considered as a
functional condition, largely reversible after a sustained weight loss. Moreover, due to the effects of the adiposity
on the regulation of the somatotropic axis, the application of GH stimulation tests in obesity may also lead to an
incorrect diagnosis of GH deﬁcieny (GHD). On the other hand, similar to patients with GHD unrelated to obesity,
the reduced GH response to stimulation testing in obese individuals is associated with increased prevalence of
cardiovascular risk factors and detrimental alterations of body composition, which contribute to worsening
their cardio-metabolic risk proﬁle. In addition, the reduced GH secretion may result in reduced serum insulin-
like growth factor (IGF)-1 levels, and the concordance of low peak GH and low IGF-1 identiﬁes a subset of
obese individualswithhigh cardiovascular risk. Furthermore, afterweight loss, the normalizationof theGH response
and IGF-1 levels may or may not occur, and in patients undergoing bariatric surgery the persistence of a low GH
status may affect the post-operative outcomes. In this review, we will provide an overview on some clinically rele-
vant aspects of the relationship between obesity axis and the somatotropic axis in the light of the recently published
research.
© 2014 Elsevier Ltd. All rights reserved.1. Introduction
Growth hormone (GH) and insulin-like growth factor (IGF)-1 are
the main regulators of linear growth [1]. However, the lifelong involve-
ment of the somatotropic axis in the regulation of metabolism and body
composition as part of the overall regulation of body weight across the
feeding/fasting cycle has become increasingly evident [2]. GH and IGF-1
play an important role in the maintenance of normal body composition,
by exerting both anabolic and catabolic actions on different tissues in
the human body, with overall stimulatory effects on protein synthesis
in muscle and lipolysis in adipose tissue [3]. Our understanding of the
complex relationship between obesity and the somatotropic axis
started to be unraveled in the 1960s from the observations that obesity
induced by lesions of the ventromedial hypothalamic nucleuswas asso-
ciated to GH suppression and reduced linear growth in animals [4].
Since then, a growing body of evidence has accrued supporting the
hypothesis that the state of the adipose tissue depots and the regulation
of the somatotropic axis are closely related [5–9].a Clinica e Chirurgia, Unità di
Pansini, 5, 80131 Naples, Italy.In spite of the considerable effort expended in producing clinical and
experimental data regarding the possible involvement of the low GH
status in amplifying the cardio-metabolic risk proﬁle in obese individuals,
the relationship between obesity and the somatotropic axis remains in-
completely understood. In this respect, the question arises of whether
the impairment of spontaneous and stimulated GH secretion that charac-
terizes obesity induces a true GH deﬁciency (GHD) according to the
current guidelines [10], or represents only an epiphenomenon of obesity,
evoking the proverbial chicken and egg question. In fact, although gener-
ally reversible after sustained weight loss, the low GH status in obese
individuals is associated with increased prevalence of cardiovascular
risk factors and detrimental alterations of body composition which con-
tribute to worsening their cardio-metabolic risk proﬁle. This review was
aimed at pinpointing some of the key aspects of the relationship between
obesity axis and GH/IGF-1 in light of recently published research.
2. Theﬁrst steps along the road: brief highlights on the GH/IGF-1 axis
The GH/IGF-1 axis is a ﬁnely tuned endocrine system with multiple
levels of control including neuroendocrinemediators, tissue and soluble
receptors, and carrier proteins [11]. Themajor physiologic and bioactive
component of GH is a 22 kDa single-chain of 191 amino acids; its
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by GH-releasing hormone (GHRH), somatostatin (SS) and GH-releasing
peptides, although a range of peripheral signals contribute to the regu-
lation. GH acts through a single transmembrane receptor (GHR) that is
structurally related to PRL and cytokine receptors. In humans, the GHR
is highly expressed in many peripheral tissues and the liver, where
GH stimulates the synthesis of IGF-1. In turn, IGF-1, the key transcrip-
tional target of GH signaling, inﬂuences GH secretion through a classic
negative feedback system. In addition to IGF-1, a number of peripheral
factors have long been recognized as key regulators of GH secretion,
along with nutritional status, glucose and fat metabolism, primarily
free fatty acids (FFA), and circulating hormones, such as insulin, ghrelin,
adiponectin, and leptin. In particular, clinical and experimental studies
show an inhibitory role of insulin on GH release and mRNA expression
of GHR [3]. IGF-1 is a single, nonglycosylated, 7.6 kDa protein integrated
in the IGF regulatory system [12]. This system consists of two ligands
(IGF-1 and IGF-2), two cell-surface receptors (type I and type II IGF re-
ceptors) and six regulatory binding proteins (IGFBP-1-6], associated
with IGFBP degrading proteases. Free IGF-1, which accounts for less
than 1% of the total circulating IGF-1, is responsible for the bioactivity
on target tissues. IGF-1 circulates within the intravascular space as part
of a ternary complex with ALS and IGFBP-3, the predominant plasma
binding globulin regulated byGH concentration, constituting both a res-
ervoir and a carrier system for IGF-1. However, IGFBP-1 and IGFBP-2 are
also important determinants of IGF-1 bioactivity, where IGFBP-1 and
IGFBP-2 are active regulators of IGF-1 effects and bioavailability, respec-
tively. Aside fromGH,many different factors have been reported to affect
IGF-1 metabolism, such as age, gender, body composition, nutritional
driven components, and glucose homeostasis [13]. Insulin is involved in
regulating the IGF system mainly through modulating the IGFBPs,
which in turn regulate insulin sensitivity via bioactive IGF-1, with a cen-
tral role for IGFBP-2; both glucose and insulin down-regulate the secre-
tion of IGFBP-1 by the liver, while insulin per se regulates IGFBP-2 [14].
GH activates multiple intracellular signal transduction pathways,
leading to the transcription of several genes, including the components
of GH/IGF-1 axis, such as IGF-1, IGFBP3, and ALS [3,15]. GH receptor
(GHR), Janus kinase (JAK)2, and signal transducer and activator of
transcription (STAT) proteins are mainly involved in GH signaling
cascade. Following the GH binding to GHR, a member of the class I cyto-
kine receptor superfamily, the tyrosine kinase JAK2 is activated. Upon
recruitment to the GHR–JAK2 complex, the STAT proteins are phosphor-
ylated, with STAT5b as the principal transcriptional effector. Two other
GH signal transduction pathways are the RAS/MAPK and the phos-
phatidylinositol 3′-kinase (PI3K)/Akt pathways. Aside from the internal-
ization of GHR, GH/IGF1 signaling is alsomodulated by the suppressors of
cytokine signaling (SOCS) 1–3, a family of intracellular proteins with a
key role in regulating cytokine-activated JAK2/STAT pathways, resulting
in a complete block of GHR-mediated signaling [3,16]. GH directly affects
adipocyte metabolism by inhibiting the lipoprotein lipase; furthermore,
GH increases the hormone-sensitive lipase activity by the activation of
the β-adrenergic receptor. Through these effects, GH stimulates the pref-
erential oxidation of lipids, directing the energy frommetabolic processes
towards the synthesis of proteins. Moreover, GH down-regulates the
expression of 11β-hydroxysteroid dehydrogenase type 1, the enzyme
that ampliﬁes the action of glucocorticoid in visceral adipose tissue by
stimulating the conversion of inactive dehydrocorticosterone to active
corticosterone [3]. GH alsomodulates the expression of lipid droplet pro-
teins, such as CIDE-A (cell-death-inducing DFF45-like effector), and the
secretion of adiponectin, thus promoting a more favorable peripheral
adipose tissue distribution [3].More recently, the evidence thatGHdiffer-
entially regulates the NF-kB activity in adipocytes and macrophages
suggests a modulating role for GH on chronic inﬂammation involved in
obesity-associated insulin resistance [17]. IGF-1 also has metabolic ac-
tions on its own in regulating lipolysis, proteolysis and insulin resistance
as part of the IGF-1/insulin system. Other effects, such as the stimulation
of preadipocyte proliferation, differentiation, and survival, are producedby the up-regulation of IGF-1 secretion. Above all, a “ﬁne tuning” of
IGF-1 signaling cascade, especially the IRS-1/PI3K/Akt pathway, is critical
for proper adipogenesis [18]. In obese individuals this integrated regula-
tory system is disrupted at multiple points and a number of central and
peripheral regulative factorsmight contribute to affecting their GH status
[9].
3. Clinical and experimental evidence linking obesity and low
GH status
Obese individuals with low GH status exhibit detrimental chang-
es in the cardiovascular risk proﬁle and body composition [19,20]
closely resembling those observed in patients with GHD syndrome
and Prader–Willi syndrome (PWS). Adult GHD syndrome is a well-
recognized acquired clinical entity commonly due to hypothalamic pitu-
itary disorders and/or their treatments, such as surgery and radiotherapy
[21]. GHDpatients commonly presentwith ametabolic syndrome charac-
terized by unfavorable plasma lipid proﬁle [22], increased cardiovascular
morbidity and detrimental changes in their body composition due to in-
creased fat mass and reduced muscle mass [10]. The increase in body
fat, mainly the intra-abdominal fat, associated with decreased bone min-
eral density, muscle strength, exercise capacity and cognitive function,
has led to the therapeutic use of GH replacement in adults with severe
GHD [23]. Interestingly, GH replacement therapy improves themetabolic
alterations and reduces the visceral adipose tissue, althoughwithminimal
changes in total body weight. PWS is the most common known genetic
cause of marked severe obesity characterized by hyperphagia, muscle
hypotonia, short stature, mental retardation, andmultiple endocrine dys-
functions, including hypogonadism and reduced GH secretory capacity.
PWS patients presented with an extreme increase in body fat mass that
is more marked than that observed in obese subjects with comparable
BMI [24]. Albeit the beneﬁcial effects of GH treatment on growth and
body composition have been clearly demonstrated in children with
PWS, epidemiological studies have pointed out the occurrence of sudden
death during initiation of GH mainly related to severe obesity and sleep-
disordered breathing, leading to a call for cessation of its use [25]. In addi-
tion, experimental animal models of altered signal-transduction involved
in the cellular responses to GHhave been produced to investigate the role
of reducedGH signaling in adiposity [26,27], such as the STAT5b knockout
mouse, the GH receptor gene disrupted, knockout, or null mouse
(GHR−/−), containing a disruption in theGH receptor/GHbinding protein
gene which completely disrupts GH signaling, or the GH receptor an-
tagonist transgenic mice expressing a GH analog which decreases GH
signaling by competing with GH for binding to the GHR. All of these
models are variably characterized by dwarﬁsm, low plasma IGF-1
concentrations and obesity.
4. Low GH status in obese individuals: the crossroad of the road
Changes in the cardiovascular risk proﬁle and body composition in
obese individuals with low GH status are associated with increased
cardio-metabolic sequelae [28–30], which are signiﬁcantly worse com-
pared to those found in obese individuals without impairments in the
somatotropic axis [31,32]. Therefore, the focus has shifted to the possible
contribution of the low GH status in amplifying the cardio-metabolic risk
proﬁle in obese individuals, likewise to GHD patients.
Major criticism considering obese individuals with low GH status as
GHD patients is that this is a functional status and that it might reverse
with weight loss. According to this view, the low GH status in obesity
represents an acquired “functional” defect, rather than a pre-existing
disorder. This issue harbors the questions of whether the presence of
the low GH status has a clinical relevance in obesity and if weight loss
does really normalize GH status. Although the exact mechanisms re-
sponsible for the altered GH secretion in obesity still need to be clariﬁed,
the vast majority of clinical data indicates that regardless of a normal
pituitary function the endogenous GH secretion is markedly reduced
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particular, the reduction in the half-life of GH is associatedwith reduction
in both frequency and amplitude of GH secretory bursts and increase in
GHmetabolic clearance rate, with the net result of low plasma GH levels
[9]. Additionally, the GH response to a number of pharmacological chal-
lenges such as the insulin tolerance test (ITT) or GHRH + arginine, is
deﬁnitely blunted [31,33]. The neuroendocrine alterations underlying
the low plasma GH levels in obesity include dysregulation of GHRH,
SS, and ghrelin pathways, although a key role is also played byperturba-
tions in obesity-relatedmetabolic factors, such as hyperinsulinemia and
excess of circulating FFA. The hyperinsulinemia associated with insulin
resistance in obesity has been reported in contributing to a reduced GH
secretion [3], likely by increasing the hypothalamic somatostatin
release. As commonly seen in obese individuals, the inhibitory role of
high circulating FFA is supported by the restoration of GH release after
the administration of the antilipolytic agent acipimox [34]. This evi-
dence indicates that high circulating FFA might be responsible for a
low GH status via the derangement of a classical endocrine feedback
loop between GH and FFA released by GH-induced lipolysis. Similarly,
Orlistat, a gastrointestinal lipase-inhibitor, is effective in inducing a
weight-independent increase in peak stimulated GH, IGF-1 levels, and
IGF-1/IGFBP-3 ratio along with reduction in post-prandial FFA [35].
The acute reduction in circulating FFA induced by acipimox signiﬁcantly
increases the stimulated GH secretion only in obese individuals without
organic GHD [36]. Regardless of FFA, a chronic state of leptin or insulin
excess, as well as overeating per se or deﬁcient ghrelin secretion, prob-
ably contributes to the impaired GH secretion. In addition, the severity
of the defect in GH secretion is proportional to the degree of obesity,
and an increase in each unit of body mass index (BMI) reduces the
daily secretion of GH by 6% [37]. Currently, the central point is whether
the reduced GH secretion in obesity might also result in reduced serum
IGF-1 levels, thus conﬁguring a true clinical condition of GHD. This is
particularly relevant considering the close link between low IGF-1
levels and the pathogenesis of type 2 diabetes, metabolic syndrome,
cardiovascular disease, and chronic inﬂammation [38,39]. In fact, a
number of clinical studies showed that unlike patients with GHD unre-
lated to obesity, where total and free IGF-1 levels aremainly lower than
in healthy controls [8], in obese individuals total IGF-1 may not be re-
duced to the degree predicted by GH levels; furthermore, other studies
have reported relatively increased amounts of free IGF-1which could be
responsible for an enhanced feedback inhibition of GH release [40].
With particular regard to free IGF-1 determinations, these conﬂicting
results could reﬂect methodological differences throughout the studies.
Nevertheless, the heterogeneity in IGF-1 levels might partly be due to
the effects on the IGF regulatory system of different factors associated
with obesity, such as adipose tissue distribution, glucose homeostasis,
hyperinsulinemia, and FFA. More importantly, the hyperinsulinemia
associated with insulin resistance in obesity may variably inﬂuence
free IGF-1 levels, linked to a concomitant reduction in IGFBP-1 and
IGFBP-2 levels and high IGFBP proteolysis activity, which in turn are re-
sponsible for the negative feedback on somatotropic cells [41]. Both
IGF-1/IGFBP-3 molar ratio, a rough estimate of free IGF-1, and ultra-
ﬁltrated free IGF-1 have been found to be signiﬁcantly decreased in obe-
sity; however, visceral adipose tissue, rather than adiposity per se, has
been reported to correlate inversely with circulating total IGF-1 levels
[8,42]. Anyway, the biological activity of IGF-1 measured as bioactive
IGF-1, a method which incorporates the complex interactions between
IGF-1, IGF-2, IGFBPs, proteases, and the IGF-1 receptor, might not be re-
duced in obese individuals [41]. In obesity this ﬁnding suggested that
the enhanced sensitivity to GH at the level of the liver could maintain
a normal IGF-1 activity despite the severely reduced endogenousGH se-
cretion. Low IGF-1/IGFBP-3molar ratio and low IGF-1 levelswere found
in individuals with hepatic steatosis, as a marker of a common pathway
linking hepatic steatosis and low IGF-1 to metabolic syndrome and
atherosclerosis [43]. Accordingly, we reported a signiﬁcant negative
correlation between components of the IGF-1 axis and the severityhepatic steatosis in overweight/obese subjects [44]. In this complex
scenario, the strongest evidence is the link between increased visceral
adiposity and low somatotropic axis. A number of factors arising from
excess ectopic fat storage (e.g. visceral, epicardial or liver fat), including
pro-inﬂammatory mediators, can independently affect the secretory
mechanisms of GH and IGF-1 and reduce IGF-1 bioactivity [45]. There-
fore, it is possible that the combination of multiple perturbations
along the somatotropic axis might be responsible for different degrees
of impairments of GH and IGF-1 secretion in obese individuals. The
hypothetical maladaptive mechanisms likely involved in the network
operating between obesity and the somatotropic axis are shown in
Fig. 1. The concordance of low GH and low IGF-1 could have patho-
physiologic relevance in increasing the accrual of adipose tissue and
contributing to long-term metabolic and cardiovascular complications
in obese individuals. In this respect, a recent report by Stanley [46] has
demonstrated that low IGF-1 circulating levels and low peak stimulated
GH in obesity were not always associated in the same obese individuals
of both genders; however, if thiswere the case, then this association iden-
tiﬁed a subset of obese individuals with an increased cardiovascular risk.
In particular, obese individuals with reduction of either IGF-1 or peak
stimulated GH presented higher carotid intima-media thickness com-
pared to an obese peer with normal IGF-1 and peak stimulated GH. In
line with these data, we have also previously reported a discordance be-
tween peak stimulated GH and IGF-1 in obese females who were candi-
dates for bariatric surgery [47], although in our series the discordance
rate is far lower than in those reported by Stanley [46] (8.3% vs 31.6%).
However, phenotypic characteristics of the subjects studied, for example
degree of obesity, age and gender, may have accounted for the different
discordance rates between the two series. These ﬁndings provide evi-
dence that obese individuals could be present with an effective, though
functional and reversible, low GH status. This condition might serve as a
vicious circle that is reinforced with further accumulation of ectopic adi-
pose tissue and increase in cardio-metabolic risk factors. In contrast, Pijl
[48] found that, by using the deconvolution analysis of 24-h plasma GH
concentration proﬁles, the GH neurosecretion remained altered after
weight loss in premenopausal women with large visceral fat area,
suggesting a primary role for hyposomatotropism in favoring the
preferentially store excess fat in visceral adipose tissue in these
women. In this regard, variable degrees of impairment of the somato-
tropic axis may be part of the maladaptive endocrine-metabolic changes
likely responsible for the phenotypic variability among equally obese
subjects [8,49].
The restoration of GH status alongwith weight loss, the long-lasting
maintenance of weight loss in obese patients after bariatric surgery
offers an interesting opportunity to evaluate this statement. Stimulated
GH secretion signiﬁcantly increases after biliopancreatic diversion
(BPD) [50]. Partial recovery of GH secretion is also observed after
Roux-en-Y gastric bypass (RYGB) [51]. On the other hand, although
with some discrepancy [52,53], post-operative IGF-1 secretion shows
a long-lasting impairment, similarly to that evidenced after nonsurgical
weight loss, presumably linked to the catabolic state induced by BPD
[54] and RYGB [55]. In the same series of obese female candidates for
bariatric surgery reported above [47], we found that after laparoscopic
adjustable gastric banding about a third of the patients with baseline
low GH status restored their peak GH response: However, another
ﬁfth had IGF-1 levels still below the normal range calculated according
to age normative ranges [10], with a post-operative discordance rate
that was more than double the pre-operative value (8.3% vs 19.4%).
Hence, likewise to weight loss after a long-term calorie restriction [8],
the increase in IGF-1 levels along with the restoration of GH response
to stimulation testing may or may not occur after bariatric surgery. In
this context, the dissociation between GH and IGF-1 might be a marker
of a subtle and persistent catabolic state probably due to bariatric proce-
dures. Interestingly, excess of weight loss and fat mass loss were higher
in patients who normalized their GH/IGF-1 axis after surgery than in
those who did not [47]. We veriﬁed the inﬂuence of persistent failures
Fig. 1. The hypothetical maladaptive mechanisms likely involved in the etiopathogenesis of obesity-related alterations in GH/IGF-1 axis. The elevation of circulating FFA, adipokines and
cytokines induced by increased visceral adipose tissue or other ectopic fat depots, such as hepatic steatosis or epicardial fat, is responsible for insulin resistance and is also able tomarkedly
affect the normal feed-back control systemoperating in the GH/IGF-1 axis. The “functional” lowGH/IGF-1 axis, on turn,might act on body composition by inducing unfavorable changes in
body composition similarly to those observed in GHD, therefore contributing to worsen the insulin resistance state and the associated metabolic sequele. SS, somatostatin; GHRH, growth
hormone-releasing hormone; GH, growth hormone; IGF-1, insulin-like growth factor-1; FFA, free fatty acids.
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a larger series of obese subjects of both genders, allowing us to suggest
the investigation of GH/IGF-1 axis in the pre-operative evaluation of
obese candidates for bariatric surgery [49].
5. Further steps along the road: how to diagnose low GH status
in obesity
Body fat, metabolic and nutritional status are the main confounding
factors in the interpretation of biochemical tests commonly used in the
diagnosis of GHD [10]. Adiposity might account for about 20% of the
variability in peak GH response after provocative tests in both children
[56] and in adults; it has been calculated that the GH response after
GHRH + arginine testing was reduced 1.02 μg/L for each 1 cm increase
in waist circumference, independent of BMI [33], and waist circumfer-
ence represents the main predictor of low peak GH [57]. Considering
the pulsatile nature of GH secretion, a correct diagnosis would require
multiple sampling to obtain a 24-hour integrated GH proﬁle. Conversely,
serum IGF-1 and IGFBP-3 levels show only minor ﬂuctuations and
represent a stable and integrated measurement of GH production and
its peripheral effects. Nevertheless, although IGF-1 levels b2 standard de-
viation below the age-matched mean is strong evidence for signiﬁcant
GHD, a provocative test of GH reserve is required for many adultpatients with suspected GHD. The assessment of the GH secretion is
commonly performed using pharmacological challenges such as ITT or
GHRH + arginine. The latter one, using the effect of arginine in poten-
tiating the response to GHRH via inhibition of the hypothalamic release
of somatostatin, is currently considered the favorite diagnostic tool
due to its high speciﬁcity and sensitivity, as well as tolerability [36].
GHRH + arginine is also the only test for which BMI-dependent
variability of GH responsiveness has been investigated [58], with the
deﬁnition of 4.2 μg/L as the appropriate GH cut-off in adults with
BMI N 30 kg/m2 [59]. Using this new cutoff value of the GHRH+ arginine
test, about 1/3morbidly obese individuals presented a lowpeak stimulat-
edGH [31]. Very recently a 1-μg/L peakGH cutoff level for the diagnosis of
adult GHD in overweight/obese individuals using the glucagon stimula-
tion test has been provided [60].
Important criticism to the application of GH stimulation tests in
obesity is that it might lead to an uncorrect diagnosis of GHD [61],
particularly in obese children [62]. The overdiagnosis of GHD could be
of great relevance, especially in view of a possible unjustiﬁed treatment
with GH. However, considering the high burden of cardiovascular risk
factors linked to low GH status, the evaluation of GH/IGF-1 axis could
correctly identify different cardiovascular risk phenotypes among
equally obese individuals, especially when the low GH secretion is
paralleled by low IGF-1 levels.
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There are considerable controversies about the potential use of
recombinant human (rh) GH as an adjuvant therapy in a weight loss
program for obese individuals. Indeed, no government-agency ap-
proved rhGH as pharmaceutic agents speciﬁcally for the treatment of
obesity. Thus, to date, rhGH is not a standard-of-care to obese patients,
moreover considering the side-effects of this therapy, including hyper-
glycemia. However, a large number of clinical and experimental studies
show the favorable effects of rhGH treatment on body composition in
obesity, also independently ofweight loss, and suggest a true physiologic
role of the GH/IGF-1 axis inmediating some of the co-morbidities associ-
ated with obesity. A recent review by Berryman [9] on the efﬁcacy of
rhGH therapy has evidenced only limited effects on weight loss in unse-
lected obese individuals; nevertheless, this treatment has been effective
in reducing total and visceral adiposity, increasing lean body mass, and
improving lipid proﬁle and glucose metabolism. Starting from these ob-
servations and emphasizing that further data are needed before rhGH
administration can be recommended as standard-of-care to obese
patients, threemain issues arise in considering the clinical studies evalu-
ating the effectiveness of GHas a treatment in the integratemanagement
of obese individuals. These three issues can be arranged in a classic form
of who–how–when questions. First, who is the target population of
obese individuals. From a physiopathological point of view, it should be
conceivable to limit the therapy to the speciﬁc subsets of obese individ-
ualswith abnormalities of theGH/IGF-1 axis, especially involvingGH and
IGF-1 simultaneously, in relation to their worse cardio-metabolic risk
proﬁle. Unfortunately, almost all the studies have been performed in un-
selected obese adults and to date no case–control studies have been
available to compare the effectiveness of rhGH treatment in adequately
large series of GH deﬁcient and GH sufﬁcient obese individuals. A careful
investigation of GH/IGF-1 axis can represent an indispensable prerequi-
site in the evaluation of obese individuals assigned to rhGH treatment.
The main criticism to GH treatment in obesity is that the low GH status
could reverse after weight loss (8,51), althoughwith some discrepancies
(47). Nevertheless, asmentioned above, the recovery of GHand IGF-1 se-
cretion might not be the rule after weight loss [8,47,49]. The second one
is how to administer rhGH treatment properly. There is no general agree-
ment on the effective dose of rhGH treatment in obese individuals. Many
trials used relatively higher doses of GH compared to those recommend-
ed for adult GHD. Indeed, if the target population is the subsets of obese
individuals with abnormalities of the GH/IGF-1 axis, then it would be
logical to use rhGH replacement doses that normalize IGF-1 levels
according to age and gender-speciﬁc values. This physiological regimen
of rhGH replacement may also minimize the number of dose-related
side-effects, such as hypertension, arthralgia, paresthesia and peripheral
edema and reduce the unfavorable short-term effects on glucose metab-
olism, such as GH-induced hyperinsulinemia, which may oppose to the
lipolytic effect of GH. Third, the duration of the treatment: rhGH treat-
ment should be continued for a period of time sufﬁcient enough to obtain
along with weight loss the spontaneous recovery of GH/IGF-1 axis, if any,
or until beneﬁcial effects are evidenced. Indeed, improvements in glucose
metabolism are observed only in long-term studies (N12 weeks) as the
insulin-sensitizing effects due to the reduction in visceral adipose tissue
and the increase in IGF-1 levels require a longer lap of time [63]. In addi-
tion, as reported in adult GHD, low dose-GH treatment might induce
insulin-like effects through the increase in bioactive IGF-1 with a genera-
tion of IGF-1/insulin hybrid receptors at muscle levels [64]. Low dose
rhGH replacementwith normalization of IGF-1 levelsmay also be consid-
ered as an adjuvant therapy in preventing loss of fat free mass during the
early post-operative period after bariatric surgery. In a randomized con-
trolled study in morbidly obese females with persistent low GH/IGF-1
status after surgery, we have shown that rhGH replacement has resulted
in a reduction in bodyweight mainly due to fat mass loss, with a signif-
icant sparing of lean body mass and improvements of lipid proﬁle and
insulin sensitivity [65]. Finally, a role for GHRH analogues increasingendogenous GH secretion, such as tesamorelin [66], has recently dem-
onstrated to improve body composition without adversely affecting
glucose metabolism, while studies on GH fragments with predominant
antilipolytic activity have not yet yielded convincing results.
7. Conclusions
Obesity and somatotropic axis exhibit multiple and bidirectional rela-
tionships contributing to themultiplemaladaptive endocrine changes in-
volved in the pathogenesis of obesity. The low GH status in obese
individuals is functional and almost reversed by weight loss; however,
this condition is responsible for anthropometric andmetabolic alterations
increasing the cardio-metabolic risk proﬁle. This hypothesis generates the
following considerations: i) the different GH/IGF-1 axis status might be
one of the mechanisms responsible for the heterogeneity in the obese
phenotype; ii) although rhGH is not recommended as a standard-of-
care to obese patients, many clinical studies show the usefulness of GH
as an adjunctive tool in the treatment of the subset of obese individuals
with reduced GH secretory capacity and low circulating levels of IGF-1,
in relation to their worst cardio-metabolic risk proﬁle; and iii) preopera-
tively testing the GH/IGF-1 axis in obese patients candidates for bariatric
surgerymay be useful in predicting the individual post-surgical outcome,
while short term low dose treatment with rhGH resulting in normaliza-
tion of IGF-1 levels has been proven to preserve fat free mass.
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